fashion -WSS

fashion

author：leisure time 2025-10-02 10:48:47 - browse：1

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： CDC advisory group OKs chikungunya vaccine

focus

hotspot

WSS

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Sanofi CEO defends move to abandon profit guidance, boost research

Are embryos people? Reproductive medicine's future depends on the answer

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Senate panel clears PBM, hopsital reforms

explore

fashion

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Elisabeth Bik tackles the widespread issue of research misconduct

State Dept. review finds Biden bears some blame for Afghanistan failures

Ambulance rides for just $100? Advisers want major billing fixes

Duchenne breakthrough therapy leaves behind pioneering families

Extreme heat events are a public health emergency

Virginia high school admissions case could be legal follow

Doctor of U.S. President Joe Biden says he is fit for duty

Novavax promises a turnaround & Lilly roils the obesity market

A clever new way to fix Medicaid and graduate medical education

knowledge

CDC advisory group OKs chikungunya vaccine

Free speech concerns arise in wake of journal editor Eisen's firing

Ohio train derailment: Experts on toxic chemical risks

Redefining sustainability for the pharmaceutical industry

Medicare will require more price transparency from hospitals

More doctors should go into startup world

focus

explore

hotspot

hotspot